このエントリーをはてなブックマークに追加


ID 70225
FullText URL
Author
Moriwake, Takatoshi Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Tominaga, Yusuke Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Katayama, Satoshi Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaku, Haruki Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons
Tsuboi, Ichiro Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Yoshinaga, Kasumi Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Yamanoi, Tomoaki Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kawada, Tatsushi Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sadahira, Takuya Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID researchmap
Iwata, Takehiro Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID
Nishimura, Shingo Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Bekku, Kensuke Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Katayama, Yasuhiro Department of Urology, Okamura Isshindo Hospital
Araki, Motoo Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons researchmap
Abstract
Objectives: The objective of this study is to evaluate the safety and efficacy of Rezūm water vapour energy therapy (WAVE) in Japanese patients with benign prostatic hyperplasia (BPH) continuing antithrombotic therapy and to validate the Okayama University Modified Clavien-Dindo classification (OU-mCD) for perioperative hematuria.
Patients and Methods: We retrospectively analysed 80 consecutive patients who underwent WAVE from August 2023 to July 2024, including 37 (46.2%) continuing antithrombotic therapy perioperatively. Hematuria within 30 days was graded using conventional Clavien-Dindo classification and the OU-mCD, a novel classification focusing on intervention necessity. We assessed clinically significant hematuria (Grade ≥ Ib), catheter-free rate, prostate volume reduction and haemoglobin change.
Results: Clinically significant hematuria occurred in 21.6% (8/37) of patients continuing antithrombotic therapy versus 4.7% (2/43) without (p = 0.038). All 10 Grade ≥ Ib cases occurred during hospitalization with the catheter in place and were managed conservatively with continuous bladder irrigation (median 1 day); none required transfusion or surgical reintervention. Only one patient required temporary drug discontinuation. Treatment efficacy did not differ by antithrombotic status: 86.2% achieved PVR < 50 ml with 44% mean prostate volume reduction. Multivariate analysis identified antithrombotic therapy as the sole independent risk factor for Grade ≥ Ib hematuria (OR 5.46, 95% CI 1.06–28.16, p = 0.042).
Conclusion: WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade ≥Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.
Keywords
benign prostatic hyperplasia
hematuriaantithrombotic therapy
Japanese
OU-mCD
water vapour energy therapy
Published Date
2026-02
Publication Title
BJUI Compass
Volume
volume7
Issue
issue2
Publisher
Wiley
Start Page
e70170
ISSN
2688-4526
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2026 The Author(s).
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1002/bco2.70170
License
http://creativecommons.org/licenses/by/4.0/
Citation
Moriwake T, Tominaga Y, Katayama S, Kaku H, Tsuboi I, Yoshinaga K, et al. Safety and efficacy of Rezūm water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single-centre experience. BJUI Compass. 2026;7(2):e70170. https://doi.org/10.1002/bco2.70170